Vaccine Industry Code Of Conduct Would Address Potential Conflicts, Aventis Pasteur Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposal could help manufacturers “be re-embraced as partners and collaborators” in formulating vaccine policy, Aventis VP Hosbach says. ACIP no longer includes manufacturers as full participants in its working groups, the exec notes.
You may also be interested in...
Vaccine Stockpile For HHS May Be Delayed By SEC Regs
Accounting regulations hinder booking payments from HHS for products which firms stockpile themselves, Aventis VP Hosbach says. Industry may seek an SEC exemption or a change in the contract language from CDC.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.